关于心力衰竭的最新消息:新的定义和治疗方法
1Penn State University COM, 303 Benner Pike, Suite 1, State College, PA 16801, USA.
Primary care
|January 26, 2024
概括
心力衰竭的管理包括基于症状和喷射率的分期. 治疗的目的是减缓疾病的进展,减少并发症,住院和死亡.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
背景情况:
- 心力衰竭 (HF) 是一个复杂的临床综合征.
- 肝炎的特点是症状的连续性,从风险人群的早期阶段到晚期的耐火性疾病.
- 管理策略正在不断发展,以应对这种疾病的频谱.
研究的目的:
- 概述心力衰竭的分期系统.
- 描述基于射出分数的最佳治疗启动原则.
- 强调治疗的目标,以控制心力衰竭的进展和并发症.
主要方法:
- 该研究根据症状严重程度定义了心力衰竭的阶段.
- 治疗策略是根据个别的射出分数测量量量而定制的.
- 选择治疗干预措施以减轻不良结果.
主要成果:
- 阶段化为理解心力衰竭严重程度提供了一个框架.
- 射出分数是指导治疗选择的关键决定因素.
- 最佳的治疗可以降低心力衰竭进展的风险.
结论:
- 对心力衰竭管理的分阶段方法是必不可少的.
- 基于射出分数的个性化治疗改善了患者的治疗结果.
- 有效的管理可以减少心力衰竭患者的并发症,死亡率和住院费用.
更多相关视频
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K


